Veronika Petrova

Veronika Petrova

Auto-generated profile, based on publicly available information

Veronika Petrova

Victor Chang Cardiac Research Institute

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GMgeoffray monteuuis
geoffray monteuuis
USUlf Schmitz
Ulf Schmitz
VPVeronika Petrova
Veronika Petrova
PKPadraic Scott Kearney
Padraic Scott Kearney
JRJohn E.J. Rasko
John E.J. Rasko
Intron retention (IR) in cancer was for a long time overlooked by the scientific community, as it was previously considered to be an artifact of a dysfunctional spliceosome. Technological advancements made in the last decade offer unique opportunities to explore the role of IR as a widespread phenomenon that contributes to the transcriptional diversity of many cancers. Numerous studies in cancer have shed light on dysregulation of cellular mechanisms that lead to aberrant and pathologic IR. IR is not merely a mechanism of gene regulation, but rather it can mediate cancer pathogenesis and therapeutic resistance in various human diseases. The burden of IR in cancer is governed by perturbations to mechanisms known to regulate this phenomenon and include epigenetic variation, mutations within the gene body, and splicing factor dysregulation. This review summarizes possible causes for aberrant IR and discusses the role of IR in therapy or as a consequence of disease treatment. As neoepitopes originating from retained introns can be presented on the cancer cell surface, the development of personalized cancer vaccines based on IR-derived neoepitopes should be considered. Ultimately, a deeper comprehension about the origins and consequences of aberrant IR may aid in the development of such personalized cancer vaccines.

31 March 2023
Verified
Other
Open access
GMgeoffray monteuuis
geoffray monteuuis
USUlf Schmitz
Ulf Schmitz
VPVeronika Petrova
Veronika Petrova
PKPadraic S. Kearney
Padraic S. Kearney
JRJohn E.J. Rasko
John E.J. Rasko
Intron retention (IR) in cancer was for a long time overlooked by the scientific community, as it was previously considered to be an artifact of a dysfunctional spliceosome. Technological advancements made in the last decade offer unique opportunities to explore the role of IR as a widespread phenomenon that contributes to the transcriptional diversity of many cancers. Numerous studies in cancer have shed light on dysregulation of cellular mechanisms that lead to aberrant and pathologic IR. IR is not merely a mechanism of gene regulation, but rather it can mediate cancer pathogenesis and therapeutic resistance in various human diseases. The burden of IR in cancer is governed by perturbations to mechanisms known to regulate this phenomenon and include epigenetic variation, mutations within the gene body, and splicing factor dysregulation. This review summarizes possible causes for aberrant IR and discusses the role of IR in therapy or as a consequence of disease treatment. As neoepitopes originating from retained introns can be presented on the cancer cell surface, the development of personalized cancer vaccines based on IR-derived neoepitopes should be considered. Ultimately, a deeper comprehension about the origins and consequences of aberrant IR may aid in the development of such personalized cancer vaccines.

31 March 2023
Verified
Other
Open access
GMgeoffray monteuuis
geoffray monteuuis
USUlf Schmitz
Ulf Schmitz
VPVeronika Petrova
Veronika Petrova
PKPadraic S. Kearney
Padraic S. Kearney
JRJohn E.J. Rasko
John E.J. Rasko
IR in CAR-T cell treatment and a possible approach to therapy. Development of antisense oligonucleotides-based therapies to correct pathological IR events.

31 March 2023
Verified
Other
Open access
GMgeoffray monteuuis
geoffray monteuuis
USUlf Schmitz
Ulf Schmitz
VPVeronika Petrova
Veronika Petrova
PKPadraic S. Kearney
Padraic S. Kearney
JRJohn E.J. Rasko
John E.J. Rasko
IR in CAR-T cell treatment and a possible approach to therapy. Development of antisense oligonucleotides-based therapies to correct pathological IR events.

31 March 2023
Verified
Other
Open access
GMgeoffray monteuuis
geoffray monteuuis
USUlf Schmitz
Ulf Schmitz
VPVeronika Petrova
Veronika Petrova
PKPadraic S. Kearney
Padraic S. Kearney
JRJohn E.J. Rasko
John E.J. Rasko
Intron retention (IR) in cancer was for a long time overlooked by the scientific community, as it was previously considered to be an artifact of a dysfunctional spliceosome. Technological advancements made in the last decade offer unique opportunities to explore the role of IR as a widespread phenomenon that contributes to the transcriptional diversity of many cancers. Numerous studies in cancer have shed light on dysregulation of cellular mechanisms that lead to aberrant and pathologic IR. IR is not merely a mechanism of gene regulation, but rather it can mediate cancer pathogenesis and therapeutic resistance in various human diseases. The burden of IR in cancer is governed by perturbations to mechanisms known to regulate this phenomenon and include epigenetic variation, mutations within the gene body, and splicing factor dysregulation. This review summarizes possible causes for aberrant IR and discusses the role of IR in therapy or as a consequence of disease treatment. As neoepitopes originating from retained introns can be presented on the cancer cell surface, the development of personalized cancer vaccines based on IR-derived neoepitopes should be considered. Ultimately, a deeper comprehension about the origins and consequences of aberrant IR may aid in the development of such personalized cancer vaccines.